〔Abstract〕 Objective To observe the clinical effect of ipratropium bromide and budesonide in children with bronchial asthma and allergic rhinitis. Methods 100 children with bronchial asthma and allergic rhinitis admitted to the Fifth Affiliated Hospital of Zhengzhou University from January 2021 to December 2022 were selected as the research subjects, and they were divided into an observation group and a control group. Children in the observation group were treated with ipratropium bromide, and children in the control group were given budesonide with 50 cases in each group. After treatment intervention, the clinical efficacy, inflammatory factor level, T lymphocyte subset level, lung function, and quality of life were compared between the two groups. Results The clinical efficacy rate of the children in the observation group was higher than that in the control group, and the difference was statistically significant (P < 0.05). The levels of serum interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and hypersensitive C-reactive protein (hs-CRP) of the children in the observation group were lower than those in the control group, and the differences were statistically significant (P < 0.05). The levels of CD3⁺ and CD4⁺ of the children in the observation group were higher than those in the control group, and the levels of CD8⁺ was lower than that in the control group, and the differences were statistically significant (P < 0.05). Forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and forced expiratory volume in one second/ forced vital capacity (FEV1/FVC) in the observation group of the children were higher than those in the control group, and the differences were statistically significant (P < 0.05). Conclusion The treatment of ipratropium bromide and budesonide is used in clinical treatment of pediatric bronchial asthma and allergic rhinitis, and the effect is good. The clinical symptoms of children can not only be improved, but also improve the lung function level of children.